Literature DB >> 20840469

Anti-inflammatory effects of the R2 peptide, an inhibitor of transglutaminase 2, in a mouse model of allergic asthma, induced by ovalbumin.

Dae Yong Kim1, Bum Soo Park, Gwan Ui Hong, Byung Jae Lee, Jung Won Park, Soo Youl Kim, Jai Youl Ro.   

Abstract

BACKGROUND AND
PURPOSE: Transglutaminase 2 (TGase 2) expression is increased in inflammatory diseases, and TGase 2 inhibitors block these increases. We examined whether the R2 peptide inhibited the expression of TGase 2 in a mouse model of inflammatory allergic asthma. EXPERIMENTAL APPROACH: C57BL/6 mice were sensitized and challenged by ovalbumin (OVA) to induce asthma. OVA-specific serum IgE and leukotrienes (LTs) levels were measured by enzyme-linked immunosorbent assay. Recruitment of inflammatory cells into bronchoalveolar lavage (BAL) fluid or lung tissues and goblet cell hyperplasia were assessed histologically. Airway hyperresponsiveness was determined in a barometric plethysmographic chamber. Expression of TGase 2, eosinophil major basic protein (EMBP), the adhesion molecule vascular cell adhesion molecule-1, Muc5ac and phospholipase A(2) (PLA(2) ) protein were determined by Western blot. Expression of mRNAs of Muc5ac, cytokines, matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) were measured by reverse transcriptase-polymerase chain reaction and nuclear factor-κB (NF-κB) by electrophoretic mobility shift assay. KEY
RESULTS: R2 peptide reduced OVA-specific IgE levels; the number of total inflammatory cells, macrophages, neutrophils, lymphocytes and eosinophils in BAL fluid and the number of goblet cells. Airway hyperresponsiveness, TGase 2 and EMBP levels, mRNA levels of interleukin (IL)-4, IL-5, IL-6, IL-8, IL-13, RANTES, tumour necrosis factor-α, and MMP2/9, Muc5ac, NF-κB activity, PLA(2) activity and expressions, and LT levels in BAL cells and lung tissues were all reduced by R2 peptide. R2 peptide also restored expression of TIMP1/2. CONCLUSION AND IMPLICATIONS: R2 peptide reduced allergic responses by regulating NF-κB/TGase 2 activity in a mouse model of allergic asthma. This peptide may be useful in the treatment of allergic asthma.
© 2010 The Authors. British Journal of Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20840469      PMCID: PMC3012417          DOI: 10.1111/j.1476-5381.2010.01033.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

1.  Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases.

Authors:  D Sánchez; L Tucková; P Sebo; M Michalak; A Whelan; I Sterzl; L Jelínková; E Havrdová; M Imramovská; Z Benes; S Krupicková; H Tlaskalová-Hogenová
Journal:  J Autoimmun       Date:  2000-12       Impact factor: 7.094

Review 2.  Chemokines in asthma: cooperative interaction between chemokines and IL-13.

Authors:  Nives Zimmermann; Gurjit Khurana Hershey; Paul S Foster; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

3.  Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease.

Authors:  B A Citron; K S SantaCruz; P J Davies; B W Festoff
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

4.  Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression.

Authors:  C L Ordoñez; R Khashayar; H H Wong; R Ferrando; R Wu; D M Hyde; J A Hotchkiss; Y Zhang; A Novikov; G Dolganov; J V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

5.  IFN-gamma induces transglutaminase 2 expression in rat small intestinal cells.

Authors:  Soo-Youl Kim; Eun-Joo Jeong; Peter M Steinert
Journal:  J Interferon Cytokine Res       Date:  2002-06       Impact factor: 2.607

6.  Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Authors:  Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

Review 7.  Matrix metalloproteinase-9 in lung remodeling.

Authors:  Jeffrey J Atkinson; Robert M Senior
Journal:  Am J Respir Cell Mol Biol       Date:  2003-01       Impact factor: 6.914

8.  Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS.

Authors:  Eleanor S Roberts; Michelle A Zandonatti; Debbie D Watry; Lisa J Madden; Steven J Henriksen; Michael A Taffe; Howard S Fox
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

9.  Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

Authors:  Joonhong Sohn; Tae-Im Kim; Young-Hee Yoon; Joo-Yong Kim; Soo-Youl Kim
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 10.  Emerging immune targets for the therapy of allergic asthma.

Authors:  David B Corry
Journal:  Nat Rev Drug Discov       Date:  2002-01       Impact factor: 84.694

View more
  20 in total

Review 1.  Transglutaminase 2-mediated serotonylation in pulmonary hypertension.

Authors:  K C Penumatsa; B L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-27       Impact factor: 5.464

2.  Eosinophil Peroxidase Catalyzed Protein Carbamylation Participates in Asthma.

Authors:  Zeneng Wang; Joseph A DiDonato; Jennifer Buffa; Suzy A Comhair; Mark A Aronica; Raed A Dweik; Nancy A Lee; James J Lee; Mary Jane Thomassen; Mani Kavuru; Serpil C Erzurum; Stanley L Hazen
Journal:  J Biol Chem       Date:  2016-09-01       Impact factor: 5.157

3.  Basophils as a primary inducer of the T helper type 2 immunity in ovalbumin-induced allergic airway inflammation.

Authors:  Wenwei Zhong; Wen Su; Yanjie Zhang; Qi Liu; Jinhong Wu; Caixia Di; Zili Zhang; Zhenwei Xia
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

Review 4.  Role of cells and mediators in exercise-induced bronchoconstriction.

Authors:  Teal S Hallstrand; William A Altemeier; Moira L Aitken; William R Henderson
Journal:  Immunol Allergy Clin North Am       Date:  2013-03-29       Impact factor: 3.479

5.  Regulation of allergic lung inflammation by endothelial cell transglutaminase 2.

Authors:  Frank Soveg; Hiam Abdala-Valencia; Jackson Campbell; Luisa Morales-Nebreda; Gökhan M Mutlu; Joan M Cook-Mills
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-07-24       Impact factor: 5.464

Review 6.  Epithelial regulation of eicosanoid production in asthma.

Authors:  Teal S Hallstrand; Ying Lai; William R Henderson; William A Altemeier; Michael H Gelb
Journal:  Pulm Pharmacol Ther       Date:  2012-12       Impact factor: 3.410

7.  Inhibition of allergic inflammation by supplementation with 5-hydroxytryptophan.

Authors:  Hiam Abdala-Valencia; Sergejs Berdnikovs; Christine A McCary; Daniela Urick; Riti Mahadevia; Michelle E Marchese; Kelsey Swartz; Lakiea Wright; Gökhan M Mutlu; Joan M Cook-Mills
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-07-27       Impact factor: 5.464

8.  Regulation and function of epithelial secreted phospholipase A2 group X in asthma.

Authors:  Teal S Hallstrand; Ying Lai; William A Altemeier; Cara L Appel; Brian Johnson; Charles W Frevert; Kelly L Hudkins; James G Bollinger; Prescott G Woodruff; Dallas M Hyde; William R Henderson; Michael H Gelb
Journal:  Am J Respir Crit Care Med       Date:  2013-07-01       Impact factor: 21.405

Review 9.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

10.  Transglutaminase II/microRNA-218/-181a loop regulates positive feedback relationship between allergic inflammation and tumor metastasis.

Authors:  Sangkyung Eom; Youngmi Kim; Misun Kim; Deokbum Park; Hansoo Lee; Yun Sil Lee; Jongseon Choe; Young Myeong Kim; Dooil Jeoung
Journal:  J Biol Chem       Date:  2014-09-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.